Caris Life Sciences Enhances Cancer Diagnosis with AI-Based Tool

Caris Life Sciences has published a study showcasing the capabilities of its AI-based tool, Caris GPSai, in enhancing diagnostic accuracy for cancers of unknown primary and misclassified tumors, announced in a press release. The tool, which utilizes deep learning and comprehensive sequencing, demonstrated a 95% accuracy rate in identifying tumor tissue of origin in non-CUP cases.

Caris GPSai, part of Caris' molecular profiling platform, was trained on data from over 200,000 cases and classifies tumors into 90 categories. In clinical use over eight months, the tool changed diagnoses in 704 patients, impacting treatment eligibility in 86.1% of these cases. This advancement underscores the potential of AI in precision oncology, enabling more informed treatment decisions and improving patient outcomes.